• What's involved: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Primary Biliary Cholangitis Who Have an Inadequate Response or Are Intolerant to UDCA
  • Take part: Closed
  • Principal Investigator: Professor Stephen Ryder
Research Theme | Gastrointestinal & Liver

What's involved

A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Primary Biliary Cholangitis Who Have an Inadequate Response or Are Intolerant to UDCA

Principal Investigator

Professor Stephen Ryder

Take part

Closed
Back to all trials

Website by Volute